ReviewJournal of clinical medicine2024
Heart Failure with Preserved Ejection Fraction: How to Deal with This Chameleon.
Review in Journal of clinical medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Clinical Advances in Heart Failure with Preserved Ejection Fraction: A Systematic Review of Therapeutic and Mechanistic Evidence.Vascular health and risk management · 2026Pooled it
- Vericiguat in Elderly Patients with Heart Failure and Reduced Ejection Fraction: Clinical Perspectives from Pathophysiology to Implementation.Journal of clinical medicine · 2026Review
- ANMCO position paper E-health integration in cardiology clinical care framework.European heart journal supplements : journal of the European Society of Cardiology · 2026Article
- The impact of misdiagnosed heart failure and cardiac or extra-cardiac disease burden on the prognosis in patients with type 2 diabetes.BMC cardiovascular disorders · 2026Observational
- Gut-Heart Axis in HFpEF: The Emerging Role of Microbiome-Driven Inflammation and Endothelial Dysfunction.Biomolecules · 2026Review
- Cross-cutting circuits in heart failure with preserved ejection fraction: Integrating adipokine biology, mechanotransduction, and precision targeting.International journal of biological sciences · 2026Review
- Heart failure with preserved ejection fraction, from pathophysiology to technology tools aim improve patients' management.Heart failure reviews · 2025Review
- Article
- The Multidisciplinary Approach to GLP-1 RA and SGLT2 Inhibitors in Cardiometabolic Care: A New Era for Patients with Diabetes and Heart Disease.Journal of clinical medicine · 2025Article
- Management of Atrial Fibrillation in Elderly Patients: A Whole New Ballgame?Journal of clinical medicine · 2025Review
- Multidisciplinary Approach in Atrial Fibrillation: As Good as Gold.Journal of clinical medicine · 2024Review
- A Look at Primary and Secondary Prevention in the Elderly: The Two Sides of the Same Coin.Journal of clinical medicine · 2024Review
- A Comprehensive Geriatric Workup and Frailty Assessment in Older Patients with Severe Aortic Stenosis.Journal of clinical medicine · 2024Review
- How to Manage Beta-Blockade in Older Heart Failure Patients: A Scoping Review.Journal of clinical medicine · 2024Article
- Misdiagnosis of Chronic Heart Failure in Patients with Type 2 Diabetes Mellitus in Primary Care: A Report of Two Cases and Literature Review.Vascular health and risk management · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure with preserved ejection fraction (HFpEF) is characterized by a notable heterogeneity in both phenotypic and pathophysiological features, with a growing incidence due to the increase in median age and comorbidities such as obesity, arterial hypertension, and cardiometabolic disease. In recent decades, the development of new pharmacological and non-pharmacological options has significantly impacted outcomes, improving clinical status and reducing mortality. Moreover, a more personalized and accurate therapeutic management has been demonstrated to enhance the quality of life, diminish hospitalizations, and improve overall survival. Therefore, assessing the peculiarities of patients with HFpEF is crucial in order to obtain a better understanding of this disorder. Importantly, comorbidities have been shown to influence symptoms and prognosis, and, consequently, they should be carefully addressed. In this sense, it is mandatory to join forces with a multidisciplinary team in order to achieve high-quality care. However, HFpEF remains largely under-recognized and under-treated in clinical practice, and the diagnostic and therapeutic management of these patients remains challenging. The aim of this paper is to articulate a pragmatic approach for patients with HFpEF focusing on the etiology, diagnosis, and treatment of HFpEF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.